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Accumulating evidence suggests a direct role for cigarette smoke in pulmonary vascular remodeling, which contributes to the
developmentofpulmonaryhypertension.However,themolecularmechanismsunderlyingthisprocessremainpoorlyunderstood.
Platelet-derived growth factor (PDGF) is a potential mitogen and chemoattractant implicated in several biological processes,
including cell survival, proliferation, and migration. In this study, we investigated the eﬀect of cigarette smoke extract (CSE)
on cell proliferation of rat pulmonary artery smooth muscle cells (rPASMCs). We found that stimulation of rPASMCs with CSE
signiﬁcantly increased cell proliferation and promoted cell cycle progression from G1 phase to the S and G2 phases. CSE treatment
also signiﬁcantly upregulated the mRNA and protein levels of PDGFB and PDGFRβ. Our study also revealed that Rottlerin, an
inhibitor of PKCδ signaling, prevented CSE-induced cell proliferation, attenuated the increase of S and G2 phase populations
induced by CSE treatment, and downregulated PDGFB and PDGFRβ mRNA and protein levels in rPASMCs exposed to CSE.
Collectively, our data demonstrated that CSE-induced cell proliferation of rPASMCs involved upregulation of the PKCδ-PDGFB
pathway.
1.Introduction
Pulmonary arterial hypertension (PAH) is a severe condition
that frequently leads to right ventricular failure and death
[1, 2]. Remodeling of small pulmonary arteries represents
the main pathologic ﬁnding related to PAH. The remodeling
process includes marked proliferation of pulmonary artery
smooth muscle cells (PASMCs) that contribute to vascular
wall hypertrophy [1, 3].
Studies in both animal models and in human patients
have shown that cigarette smoke exerts a direct eﬀect on pul-
monary vascular structure, resulting in pulmonary vascular
remodeling and pulmonary hypertension [4, 5]. However,
the molecular mechanisms underlying this process remain
unclear.
Platelet-derived growth factor (PDGF) is a potent mito-
gen and chemoattractant for pulmonary vascular smooth
muscle cells [6]. Although there are several PDGF family
members (A, B, C, and D), PDGFB is a prime candidate to
study, because the PDGFB isoform is a potent inducer of
VSMC proliferation and only acts through the beta-subunits
of the PDGF receptor (PDGFR) [6–8]. The upregulated
expression of PDGF and PDGFR has been correlated with
PAH in various experimental animal models [9, 10] and in
humans [11]. However, whether PDGF is also activated in
rPASMCs by cigarette smoke extract (CSE) has not been
explored.
Protein kinase C (PKC) is a crucial family of the serine-
threonine kinases in the intracellular signal transduction
pathway. It has been implicated in a variety of cellular func-
tions in vascular smooth muscle cells, including prolifera-
tion [12], apoptosis [13], and diﬀerentiation [14]. Recent
studies have shown that CSE activates PKC in monocytes
[15], bronchial epithelial cells [16], and pulmonary artery2 Journal of Biomedicine and Biotechnology
endothelial cells [17]. It has also been reported that PKCδ
plays an important role in hypoxia-induced proliferation of
PASMCs [18]. Based on this background, we hypothesize
thatCSEmayactivatePKCδ tostimulatePDGFBandactivate
a cellular response in rPASMCs.
This study was designed to examine the impact of CSE
on PKCδ expression to promote rPASMCs proliferation by
upregulating the expression of PDGFB and PDGFRβ,w h i c h
could contribute to pulmonary vascular remodeling.
2.MaterialsandMethods
2.1. Medium and Reagents. The rPASMCs were purchased
from ATCC (Jing-Ke-Hong-Da Company, Beijing, China),
and fetal bovine serum (FBS) and penicillin/streptomycin
were obtained from Gibco Life Technologies Inc. (Rockville,
MD, USA). Dulbecco’s modiﬁed Eagle’s medium (DMEM)
wasobtainedfromClontech.Themousepolyclonalantibody
against β-actin and the rabbit polyclonal antibodies against
PKCδ, piPKCδ, and Rottlerin were all purchased from
Sigma-Aldrich (St. Louis, MO, USA). Mouse monoclonal
antibodies against PDGFB and PDGFRβ were purchased
from Bioworld Technology Inc. (St. Louis Park, MN, USA).
Fluorescein isothiocyanate- (FITC-) conjugated goat anti-
rabbit IgG and horseradish peroxidase- (HRP-) conjugated
goat anti-rabbit IgG were purchased from Pierce Biotechnol-
ogyCo.Ltd(Rockford,IL,USA).Trizolreagentwasobtained
from Invitrogen (Carlsbad, CA, USA). All primers were
synthesized by Aoke Bio-Engineering Co. (Beijing, China).
2.2. Cell Culture and Treatment. Cells were cultured at 37◦C
in DMEM supplemented with 10% FBS and antibiotics
(penicillin and streptomycin) in a 5% CO2 incubator. Cells
were treated with varying concentrations of CSE (0, 2.5%,
5%, 10%, and 20%) for 24h, with or without a PKCδ
inhibitor. For all experiments, cells were made quiescent in
serum-free media for 24h before exposure to CSE. Control
untreated cells were maintained in serum-free media.
2.3. Preparation of CSE Solution. CSE was prepared as previ-
ously described by Oltmanns et al. with a few modiﬁcations
[19]. Commercial ﬁltered cigarettes (Daqianmen, Shanghai
Cigarette Factory, China), which contain 13mg of tar and
1.0mg of nicotine/cigarette, were used. Brieﬂy, cigarette
smoke derived from one cigarette was drawn slowly into
a 50mL syringe and bubbled through 30mL of DMEM at
room temperature. A cigarette yielded 5 draws with a 50mL
syringe, with each individual draw taking approximately
10 seconds to complete. The resulting solution, which was
considered 100% strength, was adjusted to pH 7.4 with con-
centrated NaOH and ﬁltered through a 0.22 μmp o r eﬁ l t e r
before diluting it into DMEM as a percentage of the total
volume. Final concentrations of the solution are expressed
as percent values ((CSE solution volume/total volume) ×
100%). Solution concentrations ranging from 0 to 20%
(0%, 2.5%, 5%, 10%, and 20%) were used to evaluate the
eﬀect of CSE on rPASMCs proliferation. The experiment was
repeated at least twice for each biological sample.
2.4. Cell Proliferation Analysis (MTT Assay). The eﬀect of
CSE treatment on cell viability and proliferation was
examined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl
tetrazolium bromide (MTT) assay. Cells (1 × 104 per well)
were seeded in 96-well plates in replicates of ﬁve. After 24h,
the absorbance at 490nm was recorded.
2.5. Cell Cycle Analysis. Flow cytometric analyses of cells
were conducted according to the manual provided with the
propidium iodide (PI) ﬂow kit (KeyGEN, Nanjing, China).
Brieﬂy, the cells were harvested and stained with PI solution
for 15min. Fluorescence was measured using a FACScalibur
apparatus (Becton Dickinson, Franklin Lakes, NJ, USA).
Data collection and analysis were performed using CellQuest
software. The percentages of cells in diﬀerent phases of
the cell cycle were determined using the software program
ModFit.
2.6. RT-PCR Assay. At o t a lo f4× 106 cells were lysed to
isolatetotalRNAusingTrizolreagent(Invitrogen),according
to the manufacturer’s instructions. Reverse transcription
(RT)wasperformedasdescribedbythecompany.TotalRNA
(5μg) was RT to synthesize cDNA in a volume of 20μL
(Reverse Transcriptase M-MLV, Takara). For every 25μLo f
PCR reaction, 1μL of cDNA was used for 20–25 cycles. PCR
products (10μL) were loaded onto a 2% agarose gel, stained
with ethidium bromide and photographed. The primer
sequences used for the RT-PCR are as follows: PDGFB
forward 5 -AAGTGAGCAGTGCCTCGGCG-3 , reverse 5 -
TGGCCTCGGGGACCGTCAAA-3 ; PDGFRβ forward 5 -
GCCGCCAGCGCCCATTTTTC-3 , reverse 5 -AGGCGT-
TTTCCTCTGCCCGC-3 ,a n dP K C δ forward 5 -AGCAGC-
GGGAGCCAGGACTA-3 ; reverse 5 -GCGGTGCGGCAT-
GTCGATGT-3 .
2.7. Immunoblot Analysis. Cells were lysed in ATM lysis
buﬀer (containing 100mM Tris-Cl, pH 7.5, 150mM NaCl,
0.2mM EDTA, 20% glycerol, 0.4% NP-40, 2% Tween-20,
and 0.2mM PMSF). The protein concentration of the super-
natant was measured with a BCA Assay Kit (Calbiochem),
and total protein (50μg) was loaded onto 15% SDS-
PAGE gels. After electrophoresis, proteins were transferred
onto PVDF membranes (Amersham) and hybridized with
primary antibodies at the following dilutions: PDGFRβ (Bio
world; Cat No: BS1764; 1:2,000), PDGFB (Bio world; Cat
No: BS1290 1:2,000), PKCδ (Sigma; 1:2,000), and phos-
phorylated PKCδ (Sigma; 1:2,000). HRP-labeled secondary
antibodies (Zhongshan Golden Bridge) were all used at a
dilution of 1:2,000. The ECL detection system (Amersham)
was used to detect the signals on the membranes.
2.8. Statistical Analysis. All data were presented as mean ±
standard deviation. Statistical analyses were carried out
using one-way ANOVA (for multiple-group comparison)
followed by the least signiﬁcant diﬀerence (LSD) test with
the computer software SPSS 12.0 (Chicago, USA). For all
tests, groups were considered statistically signiﬁcant when
P<0.05.Journal of Biomedicine and Biotechnology 3
3. Results
3.1. Eﬀect of CSE Treatment on rPASMCs Proliferation. To
investigate the eﬀect of CSE treatment on cell proliferation,
rPASMCs were stimulated with 0%, 2.5%, 5%, 10%, and
20% CSE for 24h. Cell proliferation was evaluated by MTT
colorimetric assay. As shown in Figure 1(a), CSE treatment
caused a signiﬁcant increase in cell growth in a dose-
dependent manner compared to the control group. The cell
response reached its peak at the concentration of 20% CSE.
3.2. Eﬀect of CSE Treatment on rPASMCs Cell Cycle Progres-
sion. Because cell proliferation is critically related to cell
cycle changes, we further investigated the eﬀect of CSE treat-
ment on cell cycle progression. The rPASMCs were treated
with 0%, 2.5%, 5%, 10%, and 20% CSE for 24h, cell cycle
wasexaminedusingtheFACSassaywithPIstaining.Accord-
ing to the ﬂow cytometry analysis, we found that there was
an obvious increase in the S and G2 phases in CSE-treated
cellscomparedtothenontreatedcontrolgroup.Thedataalso
indicated that there was a slight reduction in G2 phase cells
when cells were treated with CSE at concentration of 10%
(Figure 1(b)).
3.3. Eﬀect of CSE on rPASMCs PDGFB and PDGFRβ Expres-
sion. We ﬁrst investigated the eﬀect of CSE treatment on the
expression of PDGFB and PDGFRβ mRNA and protein
levels. As shown in Figure 1(c), CSE signiﬁcantly increased
the mRNA and protein levels of PDGFB and PDGFRβ
compared to the nontreated control rPASMCs.
According to the cell proliferation and cell cycle results,
we selected the 10% CSE treatment to analyze the molecular
mechanisms of CSE-induced cell proliferation. We further
investigated the eﬀect of PKCδ inhibition with Rottlerin (a
PKCδ-speciﬁc inhibitor) on upregulated cell proliferation
induced by CSE treatment. As shown in Figure 2(a), pre-
incubation of rPASMCs with Rottlerin before CSE exposure
signiﬁcantlydecreasedtheCSE-inducedincreasedcellprolif-
eration.
Since cell proliferation was reduced with Rottlerin
administration, we determined whether Rottlerin aﬀected
the cell cycle alterations with CSE treatment. As illustrated in
Figure 2(b),preincubationofrPASMCswithRottlerinbefore
CSE exposure attenuated the increase of S and G2 phase
populations induced by CSE treatment.
We also investigated the changes of mRNA and protein
levels of PKCδ after CSE treatment. We found that 10%
CSE treatment had no obvious eﬀect on total PKCδ mRNA
and protein levels. PKCδ has many diﬀerent modiﬁcations
that aﬀect its activity, including phosphorylation to generate
the active form. Therefore, we explored whether CSE treat-
ment aﬀected the phosphorylation of PKCδ.W em e a s u r e d
the phosphorylation level of PKCδ and found that CSE
treatment indeed promoted the phosphorylation of PKCδ
(Figure 2(c)).
We further investigated the eﬀect of Rottlerin on the level
of PDGFB, PDGFRβ, and phosphorylated PKCδ.C e l l sw e r e
incubated with diﬀerent concentrations of Rottlerin prior to
10% CSE treatment, harvested, lysed, and subjected to RT-
PCRorimmunoblotassay.AsshowninFigure 2(c),Rottlerin
treatment signiﬁcantly reduced the increase in PDGFB,
PDGFRβ, and phosphorylated PKCδ levels induced by CSE
treatment. These changes occurred at both the mRNA and
protein level.
4. Discussion
Cigarette smoking is a major public health problem associ-
ated with a multitude of diseases, including vascular diseases
such as atherosclerosis and pulmonary hypertension. Prolif-
eration of vascular smooth muscle cells plays an important
role in the development of these vascular diseases. The
relationship between cigarette smoking and cell function
has been explored by stimulating isolated cells with CSE to
determine direct causes [20]. In this study, we demonstrated
that CSE induced rPASMCs proliferation by upregulating
phosphorylating PKCδ and PDGFB. This stimulation was
suppressed with a PKCδ inhibitor Rottlerin, which implicate
PKCδ and PDGFB as therapeutic targets to block abnormal
smooth muscle cell proliferation induced by CSE.
Abnormal vascular smooth muscle cell proliferation
leads to medial hypertrophy of the vessel wall, vascular
remodeling, and vascular lumen narrowing, all of which
contribute to the development of pulmonary hypertension
[21, 22]. In our in vitro study, CSE signiﬁcantly promoted
the proliferation of rPASMCs. Because cell proliferation is
criticallyrelated to cellcyclechanges,we furtheranalyzed the
eﬀect of CSE on cell cycle distribution. Our study showed
that CSE promoted cell cycle progression from the G1
phase to the S phase, indicating that CSE promoted cell
proliferation. It is important to note that the results of
the current study are consistent with those obtained by
Luppi et al. [23], but contradictory to other investigations.
In particular, a report by Ambalavanan et al. found that
20% CSE did not stimulate the proliferation of neonatal
porcine vascular smooth muscle cells. Instead, CSE induced
cell necrosis in the study [24]. A major diﬀerence between
thatstudyandoursisthatneonatalporcinecellswereusedin
the former while our study used adult rat cells. The diﬀerent
CSE preparation methods between the two studies could be
another possible explanation for these discrepancies.
Many diﬀerent cell types synthesize PDGF, including
smooth muscle cells, endothelial cells, and macrophages
[25]. PDGF has the ability to induce the proliferation and
migration of smooth muscle cells and ﬁbroblasts and has
been proposed as a key mediator in the progression of
several ﬁbroproliferative disorders such as atherosclerosis,
lung ﬁbrosis, and PAH [11, 25, 26]. There is much evi-
dence to support the hypothesis that PDGF pathways play
an important role in the pulmonary vascular remodeling
process responsible in the progression of PAH [10]. Indeed,
PDGF is known to induce proliferation of smooth muscle
cellsofdiﬀerentoriginssuchastheaortaandcarotid[27,28].
Our results showed that after rPASMCs were exposed to
CSE, the expression of PDGFB and PDGFRβ mRNA and
p r o t e i nl e v e l sw e r em a r k e d l yi n c r e a s e d .I nt h ec u r r e n ts t u d y ,4 Journal of Biomedicine and Biotechnology
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Figure 1: (a) CSE promoted cell proliferation of rPASMCs. The rPASMCs were seeded in a 96-well plate and treated with increasing
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we extended the previous ﬁndings and demonstrated that
PDGF was involved in the proliferation of rPASMCs induced
by CSE.
Moreover, we investigated the molecular mechanisms by
which PDGF stimulated proliferation of rPASMCs. PKC is
a critical regulator in the intracellular signal transduction
pathway and plays an important role in PASMCs prolif-
eration [29]. Currently, 10 members in the PKC family
have been identiﬁed, and each isozyme has distinct cellular
functions [30]. There are at least four isozymes in smooth
muscle cells, including PKCδ,P K C α,P K C ε,a n dP K C ζ [31].
This study focused on the role of the PKCδ isoform in CSE-
induced rPASMCs proliferation. Although it has been shown
that PKCδ activation can induce smooth muscle cell prolif-
eration [32], Sasaguri and colleagues found that activation
of PKCα and PKCε blunted smooth muscle cell proliferation
[33]. In our study, preincubation with Rottlerin, a speciﬁc
PKCδ inhibitor, inhibited cell proliferation, caused cell cycle
arrest at the G1 phase, and downregulated PDGFB and
PDGFRβ mRNA and protein levels in rPASMCs exposed to
CSE. These results suggest that CSE induces rPASMCs pro-
liferation by upregulating PDGFB and PDGFRβ expression
mediated by the PKCδ signaling pathway.
Although the speciﬁc PKCδ inhibitor Rottlerin signif-
icantly suppressed PDGFB and PDGFRβ expression and
CSE-induced rPASMCs proliferation, the upregulation was
not completely inhibited. This result indicates that other
mediators might also be involved in the process, such as EAK
signaling,whichplaysanimportantroleinmediatinggrowth
factorfunctions.TheEAKsignalingpathwayhasbeenshown
to mediate cell proliferation in other cell types [34]. Future
studies evaluating the roles of additional signaling cascades
on cell proliferation in rPASMCs are warranted.
In conclusion, we determined that the eﬀect of CSE on
rPASMCs proliferation occurs through PKCδ and PDGFB
activation. This study provides a foundation on which to
further examine the precise roles of PDGF in pulmonary
vascular remodeling that leads to PAH. Understanding the
intracellular mechanisms responsible for rPASMCs growth
provides therapeutic targets to prevent or limit rPASMCs
proliferation and pulmonary vascular remodeling.
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